GridAI Technologies Corp. (GRDX)
$4.55-2.36%Close
BUYRECOVERY · day 8
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $15M
- Beta
- 1.70
- P/E (TTM)
- -1.06
- Short % float
- 3.53%
- Days to cover
- 1.4
- SI change
- +91.8%
- 1W
- +9.11%
- 1M
- +53.20%
- vs SPY 1W
- +9.25%
- vs SPY 1M
- +50.69%
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 0
- GROWTH
- 0
- GARP
- 3
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-33.1%
REV YoY-
ROE-55.1%
EPS YoY-
ROA-49.5%
GROSS-1532
OP-7655
NET-12790
[VALUATION]
P/E TTM-1.06
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B1.59
P/FCF-
EV/EBITDA-3.24
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E9.88
ALTMAN Z-
CURR RATIO0.16
ND/EBITDA-
BETA1.70
Company news
Loading headlines…
FAQ
- What is LOPJLB’s current signal on GRDX?
- LOPJLB’s latest quantitative signal on GridAI Technologies Corp. (GRDX) is BUY in a RECOVERY regime. Signals are updated daily.
- What market regime is GRDX in?
- GridAI Technologies Corp. (GRDX) is currently classified in the RECOVERY HMM market regime on LOPJLB.
- What does GridAI Technologies Corp. (GRDX) do?
- GridAI Technologies Corp., together with its subsidiaries, designs and develops an artificial intelligence (AI)-driven software and device platform that enables utilities, retailers, and large power users to manage load and distributed energy resources. It also develops Adrulipase, a recombinant lipase enzyme program for the treatment of exocrine pancreatic insufficiency. The company is based i…